Date: 2015-10-07
Type of information: Services contract
Compound: chemistry/computer-aided drug design (CADD), biochemical and cell assays, and in vitro and in vivo DMPK studies to improve radiotherapy treatments for cancer
Company: Charles River (USA - MA) the British Columbia Cancer Agency (Canada)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: services contract
Action mechanism:
Disease:
Details: * On October 7, 2015, Charles River Laboratories International announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an anti-bacterial drug discovery company, Pcovery, a spin-out company focused on anti-fungals, and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River’s Global Discovery Services business. As part of the agreements, Charles River’s Discovery Business will provide a comprehensive suite of in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services. For the British Columbia Cancer Agency, Charles River will begin a new project providing chemistry/computer-aided drug design (CADD), biochemical and cell assays, and in vitro and in vivo DMPK studies to improve radiotherapy treatments for cancer. For each project, the Charles River Discovery team worked closely with its respective partners, providing scientific support and insight into the development of the grant applications, and the generation and delivery of scientific presentations to the Wellcome Trust Scientific Advisory Board prior to project initiation.
Financial terms:
Latest news:
